Spotlight On... SRI pairs with Stanford on discovery project; Aptuit invests in early R&D; and much more...

SRI International's in-house CRO has teamed up with Stanford University to find some early-stage treatments for cancer and push them through preclinical development. Under what has been dubbed the SRI Biosciences-Stanford Drug Discovery and Development Program, the two institutions plan to pool their resources and expertise in hopes of hitting on first-in-class therapies for multiple forms of cancer. More

> Aptuit is investing $16 million in infrastructure and planning to hire about 90 scientists in Europe as it works to expand its share of the market for drug discovery services. News

> Evotec notched a milestone in its endometriosis-focused partnership with Bayer, advancing two projects toward clinical development. Item

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.